#USA #gene therapy #Hopewell #ProBio Inc #Viral Vector Test

ProBio Introduces a New Packaging Test for Gene Therapies

ProBio Inc., a leading contract development and manufacturing organization (CDMO) based in Hopewell, N.J., has taken a significant step forward in the realm of cell and gene therapy by launching its Viral Vector Packaging Test. This innovative service aims to address the pressing demand for expedited decision-making and mitigate risks associated with the progression of biopharma projects, especially during the transition from discovery to Chemistry, Manufacturing, and Controls (CMC).

Accelerating Innovation in Gene Therapy

The introduction of the Viral Vector Packaging Test comes at a pivotal time, as the biopharma industry seeks to shorten development timelines and streamline key processes. This offering is designed specifically for biopharma innovators who are looking for essential data and technical assurance to boost their confidence in advanced therapy programs. ProBio's commitment to enhancing its end-to-end capabilities in gene therapy and cell technology is evident with this latest service.

The test encompasses various viral vector modalities, including lentiviral vectors (LVV) and adeno-associated viruses (AAV), which are crucial for applications such as CAR T-cell therapies and gene delivery systems. By utilizing ProBio's proprietary packaging systems, the test allows researchers to achieve a rapid comparative evaluation of different packaging strategies, with turnaround times as quick as three to five weeks depending on the specifics of the program design.

Key Features of the Viral Vector Packaging Test

The Viral Vector Packaging Test incorporates several essential features aimed at providing users with reliable and robust data:

• - Consistent Development-to-CMC Continuity: This test employs the same cell lines and packaging plasmids that will be utilized in later stages of manufacturing, ensuring a smooth and predictable transition from development to CMC.
• - Platform Processes: By generating representative materials during both upstream and downstream processes, users can expect an accurate assessment of vector performance.
• - In-depth Quality Assessments: The test includes rigorous evaluations of critical parameters such as physical titer, genome purity, endotoxin levels, and the full/empty ratio of viral vectors.
• - Design of Experiments (DoE) Methodology: This unique screening approach allows for systematic optimization of plasmid ratios and packaging components specifically for lentiviral vectors used in in vivo CAR-T applications.

Expert Insights from ProBio

Huiyi Zhu, the Global Line Manager for Viral Vector at ProBio Inc., expressed the importance of this new offering, stating, "Early development choices have lasting impacts on the success of cell and gene therapy programs. This new packaging test reflects our commitment to providing biopharma innovators with practical data, technical confidence, and a clear path forward, using the same systems they can later take into CMC and clinical development". Zhu's insights emphasize the magnitude of thoughtful decision-making during the early stages of therapy development—a factor that can ultimately determine the success of new treatments in the market.

Support for Critical Therapies

This launch builds upon ProBio's recent establishment of a viral vector manufacturing facility, further solidifying the company's dedication to supporting the swift advancement of cutting-edge therapies. As ProBio CDMO continues to enhance its capabilities within the gene therapy domain, it solidifies its position as a pivotal partner for biotech and pharmaceutical companies aiming to translate innovative science into meaningful treatment solutions.

For more detailed information regarding the Viral Vector Packaging Test and its potential applications in advancing cell and gene therapy development, interested parties can refer to ProBio's official website at www.ProBioCDMO.com.

Through initiatives such as this, ProBio demonstrates its ongoing commitment to fostering advancements in the evolving field of biotechnology and improving lives through innovative therapies.